Eg95: A Vaccine against Cystic Echinococcosis

Hydatidosis or cystic echinococcosis (CE) is caused by the larval stage of the tapeworm Echinococcus granulosus. This parasite is cosmopolitan in distribution and causes significant economic losses to the meat industry, mainly due to condemnation of edible offal. Echinococcosis treatment in human is very expensive as it requires extensive surgery or prolonged chemotherapy or use of both. In Asia and Africa, the vulnerable population of developing the disease is around 50 million. Office International des Epizooties (OIE) has recognized CE as a multi species disease. The parasite has acquired the capability to survive long time within the host due to a specific mechanism to evade the host immune system. A specific class of proteins known as secreted and membrane bound (S/M) proteins play key roles in the evasion mechanism. A total of 12 S/M proteins have been reported as immunodiagnostic and immunoprophylactic agents. Of these, Eg95 is a candidate antigen used for immunization of animals. Literature suggests that, Eg95 is a multi-gene family (Eg95-1 to Eg95-7) and exists in seven different isoforms. This chapter will describe minutely efficacy of Eg95 as a vaccine candidate based on animal trial and potentiality of other S/M proteins as immunodiagnostic antigen and immune evasion.

[1]  Jianbang Ding,et al.  Design of a Novel Multi-Epitope Vaccine Against Echinococcus granulosus in Immunoinformatics , 2021, Frontiers in Immunology.

[2]  E. Larrieu,et al.  Control of cystic echinococcosis: Background and prospects , 2019, Zoonoses and public health.

[3]  J. Sunder,et al.  Variability of the EG95 antigen-coding gene of Echinococcus granulosus in animal and human origin: implications for vaccine development , 2019, Journal of Genetics.

[4]  M. Donadeu,et al.  Pilot field trial of the EG95 vaccine against ovine cystic echinococcosis in Rio Negro, Argentina: 8 years of work. , 2019, Acta tropica.

[5]  R. Maizels,et al.  Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules , 2018, Immunity.

[6]  Richard D Emes,et al.  A Trematode Parasite Derived Growth Factor Binds and Exerts Influences on Host Immune Functions via Host Cytokine Receptor Complexes , 2016, PLoS pathogens.

[7]  M. Selkirk,et al.  Modulation of the Immune Response by Nematode Secreted Acetylcholinesterase Revealed by Heterologous Expression in Trypanosoma musculi , 2016, PLoS pathogens.

[8]  A. Espino,et al.  Fasciola hepatica Fatty Acid Binding Protein Inhibits TLR4 Activation and Suppresses the Inflammatory Cytokines Induced by Lipopolysaccharide In Vitro and In Vivo , 2015, The Journal of Immunology.

[9]  Angela Trieu,et al.  Probing of a human proteome microarray with a recombinant pathogen protein reveals a novel mechanism by which hookworms suppress B-cell receptor signaling. , 2015, The Journal of infectious diseases.

[10]  M. Lutz,et al.  EmTIP, a T-Cell Immunomodulatory Protein Secreted by the Tapeworm Echinococcus multilocularis Is Important for Early Metacestode Development , 2014, PLoS neglected tropical diseases.

[11]  J. Dalton,et al.  A helminth cathelicidin‐like protein suppresses antigen processing and presentation in macrophages via inhibition of lysosomal vATPase , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  J. Dalton,et al.  A Family of Helminth Molecules that Modulate Innate Cell Responses via Molecular Mimicry of Host Antimicrobial Peptides , 2011, PLoS pathogens.

[13]  C. Budke,et al.  Global Socioeconomic Impact of Cystic Echinococcosis , 2006, Emerging infectious diseases.

[14]  L. Kamenetzky,et al.  Identification and intra-specific variability analysis of secreted and membrane-bound proteins from Echinococcus granulosus. , 2006, Parasitology international.

[15]  A. Alcamí,et al.  Schistosoma mansoni secretes a chemokine binding protein with antiinflammatory activity , 2005, The Journal of experimental medicine.

[16]  C. Chow,et al.  Hydatid disease: vaccinology and development of the EG95 recombinant vaccine , 2005, Expert review of vaccines.

[17]  F. Ayala,et al.  The Echinococcus granulosus antigen B shows a high degree of genetic variability. , 2004, Experimental parasitology.

[18]  P. Bork,et al.  Alternative splicing and genome complexity , 2002, Nature Genetics.

[19]  D. Pritchard,et al.  Eotaxin Is Specifically Cleaved by Hookworm Metalloproteases Preventing Its Action In Vitro and In Vivo1 , 2000, The Journal of Immunology.

[20]  D. D. Heath,et al.  Antigenic polypeptides of Echinococcus granulosus oncospheres and definition of protective molecules , 1996, Parasite immunology.

[21]  C. Fernández,et al.  Molecular characterisation of a novel 8-kDa subunit of Echinococcus granulosus antigen B. , 1996, Molecular and biochemical parasitology.

[22]  M. Frosch,et al.  Sequence heterogeneity of the echinococcal antigen B. , 1994, Molecular and biochemical parasitology.

[23]  M. Lightowlers,et al.  Subunit composition and specificity of the major cyst fluid antigens of Echinococcus granulosus. , 1989, Molecular and biochemical parasitology.

[24]  C. Pini,et al.  Purification and partial characterization of the major antigen of Echinococcus granulosus (antigen 5) with monoclonal antibodies. , 1986, Molecular and biochemical parasitology.

[25]  J. F. Williams,et al.  Purification of lipoprotein antigens of Echinococcus granulosus from sheep hydatid fluid. , 1971, The American journal of tropical medicine and hygiene.